What else you need !!!!6 Sep 2021 11:17
Read this carefully (Looks good to me)
The preliminary findings should provide sufficient evidence to allow EML and the clinical team at SGS to evaluate the likely commercial channels for the next stage of development for AZD1656. This could include outright sale to, or partnerships with large pharma or biotech companies, raising additional external financing to fund future development, discussions with regulators, and more.
These will occur while the final definitive report is completed, which includes specific detail such as immunophenotyping data on each patient treated